Management Change/Compensation - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 2, 2024, the board of directors of BioSig Technologies, Inc. (the "Board") appointed Mr. Chris Baer as a director on the Board.

Mr. Chris Baer, age 55, joins the Board bringing more than 25 years of commercial experience in the medical device space across both large publicly held and smaller privately held organizations. He currently serves as the chief commercial officer at CDL Nuclear Technologies. He started in this role in April 2022 and prior to that from June 2019 to April 2022 he served as the vice president of commercial operations at Impulse Dynamics. He also held several commercial leadership roles in the cardiac rhythm management and electrophysiology space including vice president and general manager at St Jude Medical / Abbott. Mr. Baer holds a pharmacy degree from The University of Pittsburgh. Mr. Baer's extensive experience in the electrophysiology medical device space makes him a valuable member of our board.

Mr. Baer will serve on the Board as a director and member of the audit, nominatingand compensation committees for a term expiring at the next annual meeting of the Company's stockholders or until his successor is duly elected and qualified, or his earlier death, resignation or removal. There are no arrangements or understandings between Mr. Baer and any other person pursuant to which Mr. Baer was selected as a director. There are no transactions in which Mr. Baer has an interest requiring disclosure under item 404(a) of Regulation S-K.